Researchers at St. Jude have discovered a tumor suppressive effect by modulating non-canonical autophagy (LAP) in myeloid cells that may be useful in the development of new strategies for cancer immunotherapy by targeting components of LAP.
Targeting components of the LAP pathway for specific drug design can be used as an immunotherapy strategy that modulates the tumor microenvironment. It is well established in the literature that infiltrating monocytes and macrophages play a pivotal role in shaping the immunosuppressive tumor microenvironment. The researchers at St. Jude envision that, by modulating LAP in the innate immune cells, it will be possible to shape the function of effector T cell toward an effective, cytotoxic immune response that can eliminate human tumor cells.
LAP, Myeloid, Cancer, Autophagosome; Autophagy; LAPosome; LC3-associated phagocytosis; Phagocytosis; Tumor suppressive, modulating non-canonical autophagy
Granted Patents or Published Applications
International patent application published: WO 2018/193393 A1
Related Scientific References
Cunha et al., “LC3-associated phagocytosis at a glance.” Cell 2019 Feb 20;132(5). pii: jcs222984. doi: 10.1242/jcs.222984.
Cunha et al., "LC3-Associated Phagocytosis in Myeloid Cells Promotes Tumor Immune Tolerance" 2018, Cell 175, 429–441, October 18, 2018, Elsevier Inc. https://doi.org/10.1016/j.cell.2018.08.061
Please contact us if you are interested in licensing this technology. Contact: email@example.com
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.